CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Go back to CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study| Johnson & Johnson (NYSE: JNJ) | Delayed: 256.99 -2.37 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $259.36 | 52 Week High | $126.07 | |||
| Open | $257.50 | 52 Week Low | $94.28 | |||
| Day High | $257.75 | P/E | 53.43 | |||
| Day Low | $254.56 | EPS | $4.81 | |||
| Volume | 3,004,791 | |||||



